# A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

> **NCT06619522** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** INCB57643

## Key facts

- **NCT ID:** NCT06619522
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-11
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participant accrual
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619522, "A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06619522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*